Keeps Biopharma (A256940) Stock Overview
Engages in the research, development, production, and sale of mechanical equipment for manufacturing flat panel displays in South Korea, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A256940 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Keeps Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩10,500.00 |
| 52 Week High | ₩22,150.00 |
| 52 Week Low | ₩4,160.00 |
| Beta | 1.64 |
| 1 Month Change | -18.03% |
| 3 Month Change | -33.92% |
| 1 Year Change | 81.03% |
| 3 Year Change | 119.67% |
| 5 Year Change | -50.24% |
| Change since IPO | 77.46% |
Recent News & Updates
Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?
Sep 06
Not Many Are Piling Into Keeps Biopharma Inc. (KOSDAQ:256940) Stock Yet As It Plummets 27%
Aug 01Market Participants Recognise Keeps Biopharma Inc.'s (KOSDAQ:256940) Revenues Pushing Shares 43% Higher
Jun 17Is Keeps Biopharma (KOSDAQ:256940) A Risky Investment?
May 15Recent updates
Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?
Sep 06Not Many Are Piling Into Keeps Biopharma Inc. (KOSDAQ:256940) Stock Yet As It Plummets 27%
Aug 01Market Participants Recognise Keeps Biopharma Inc.'s (KOSDAQ:256940) Revenues Pushing Shares 43% Higher
Jun 17Is Keeps Biopharma (KOSDAQ:256940) A Risky Investment?
May 15Further Upside For Keeps Biopharma Inc. (KOSDAQ:256940) Shares Could Introduce Price Risks After 33% Bounce
Apr 18A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) 33% Share Price Climb
Feb 06KPS (KOSDAQ:256940) Takes On Some Risk With Its Use Of Debt
Jan 13A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) Share Price
Dec 06KPS (KOSDAQ:256940) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Mar 31Sentiment Still Eluding KPS Corporation (KOSDAQ:256940)
Feb 26Shareholder Returns
| A256940 | KR Semiconductor | KR Market | |
|---|---|---|---|
| 7D | 1.3% | 11.6% | 3.3% |
| 1Y | 81.0% | 87.0% | 32.8% |
Return vs Industry: A256940 underperformed the KR Semiconductor industry which returned 87% over the past year.
Return vs Market: A256940 exceeded the KR Market which returned 32.8% over the past year.
Price Volatility
| A256940 volatility | |
|---|---|
| A256940 Average Weekly Movement | 9.6% |
| Semiconductor Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 10.3% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A256940's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A256940's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 28 | Young Kim Ha | www.kpscorp.co.kr |
Keeps Biopharma Inc. engages in the research, development, production, and sale of mechanical equipment for manufacturing flat panel displays in South Korea, China, and internationally. It offers OLED equipment, inspection technologies, camera modules, precision systems, and TSP/solar products. The company is also involved in bio research and development business; waste battery recycling; and other non-ferrous metal smelting, refining, and alloy manufacturing.
Keeps Biopharma Inc. Fundamentals Summary
| A256940 fundamental statistics | |
|---|---|
| Market cap | ₩210.82b |
| Earnings (TTM) | -₩1.24b |
| Revenue (TTM) | ₩148.36b |
Is A256940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A256940 income statement (TTM) | |
|---|---|
| Revenue | ₩148.36b |
| Cost of Revenue | ₩124.93b |
| Gross Profit | ₩23.43b |
| Other Expenses | ₩24.67b |
| Earnings | -₩1.24b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -61.82 |
| Gross Margin | 15.79% |
| Net Profit Margin | -0.84% |
| Debt/Equity Ratio | 77.6% |
How did A256940 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/07 15:05 |
| End of Day Share Price | 2025/10/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Keeps Biopharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dong Hee Han | Kiwoom Securities Co., Ltd. |
| YoungSik Yoon | Shinhan Investment Corp. |
| Sun-Jae Heo | SK Securities Co., Ltd. |